Results 201 to 210 of about 138,238 (309)

First‐Line Treatment of IGHV‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Immunoglobulin heavy chain variable region‐unmutated (IGHV‐U) chronic lymphocytic leukemia (CLL) represents a biologically aggressive subgroup with limited responsiveness to chemoimmunotherapy (CIT). To clarify the comparative effectiveness of available frontline options, we conducted a comprehensive Bayesian network meta‐analysis of ...
Santino Caserta   +13 more
wiley   +1 more source

Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review. [PDF]

open access: yesJ Patient Rep Outcomes
Schroer J   +8 more
europepmc   +1 more source

Real‐world comparison of peripheral neuropathy and treatment delivery between Pola‐R‐CHP and R‐CHOP in DLBCL

open access: yes
British Journal of Haematology, EarlyView.
Nobuhiko Nakamura   +11 more
wiley   +1 more source

Bone Marrow Pathology in Cold Agglutinin‐Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B‐cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO‐HAEM5 introduced a description of the CAD‐associated lymphoproliferative disorder (CAD‐LPD) in ...
Anne‐Marie L. Becking   +6 more
wiley   +1 more source

HERV-K Envelope Induce a Humoral Response in Non-Hodgkin Lymphoma Patients. [PDF]

open access: yesCurr Microbiol
Cossu I   +7 more
europepmc   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta   +14 more
wiley   +1 more source

Non-Hodgkin Lymphoma and Tuberculosis Coexisting in the Same Cervical Lymph Node: A Case Report. [PDF]

open access: yesCureus
Taha A   +7 more
europepmc   +1 more source

Selective IL‐23 Inhibition in Conventional Treatment‐Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study

open access: yesInternational Journal of Dermatology, EarlyView.
The clinical effects of selective IL‐23 inhibition in refractory pyoderma gangrenosum, highlighting progressive ulcer healing, reduction in inflammation and pain, and steroid‐sparing effect, supporting the role of the IL‐23/Th17 axis as a therapeutic target.
Luca Bettolini   +25 more
wiley   +1 more source

Integrated Model for Predicting Cancer Therapy-Related Cardiac Dysfunction in Non-Hodgkin Lymphoma. [PDF]

open access: yesBiomedicines
Bursacovschi D   +7 more
europepmc   +1 more source

Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies

open access: yesInternational Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Neutrophil‐extracellular traps are net‐like material released by triggered neutrophils and composed of decondensed chromatin linked to nuclear proteins. Elastase, one of the fourth most represented neutrophil‐specific serine proteases stored in azurophil granules of naïve neutrophils, exerts various actions, including degradation ...
Pasqualina Scala   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy